Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Abacavir and cardiovascular risk: reviewing the evidence.

Costagliola D, Lang S, Mary-Krause M, Boccara F.

Curr HIV/AIDS Rep. 2010 Aug;7(3):127-33. doi: 10.1007/s11904-010-0047-3. Review.

PMID:
20521126
2.

Heart attack risk with abacavir and didanosine.

[No authors listed]

AIDS Patient Care STDS. 2008 Apr;22(4):346-7. No abstract available.

PMID:
18434947
3.

'Fine tuning' HIV therapy. Report on the 9th Conference on Retroviruses and Opportunistic Infections.

Linde M.

Posit Living. 2002 Apr-May;11(3):8-9, 16, 44. No abstract available.

PMID:
12035759
4.
5.

Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.

Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, Boccara F, Costagliola D; Clinical Epidemiology Group of the French Hospital Database on HIV.

Arch Intern Med. 2010 Jul 26;170(14):1228-38. doi: 10.1001/archinternmed.2010.197.

PMID:
20660842
6.

Anti-HIV agents. Controversial findings on abacavir and heart attacks.

[No authors listed]

TreatmentUpdate. 2008 Mar;20(2):1-5. No abstract available.

PMID:
18661643
7.

Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Abacavir and CVD--again.

Sax PE.

J Watch AIDS Clin Care. 2009 Oct;21(10):81. No abstract available.

PMID:
20458812
8.

Implementing the number needed to harm in clinical practice: risk of myocardial infarction in HIV-1-infected patients treated with abacavir.

Kowalska JD, Kirk O, Mocroft A, Høj L, Friis-Møller N, Reiss P, Weller I, Lundgren JD.

HIV Med. 2010 Mar;11(3):200-8. doi: 10.1111/j.1468-1293.2009.00763.x. Epub 2009 Oct 27.

9.

Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data.

Cruciani M, Zanichelli V, Serpelloni G, Bosco O, Malena M, Mazzi R, Mengoli C, Parisi SG, Moyle G.

AIDS. 2011 Oct 23;25(16):1993-2004. doi: 10.1097/QAD.0b013e328349c6ee. Review.

PMID:
21716077
10.

Abacavir and cardiovascular risk.

Behrens GM, Reiss P.

Curr Opin Infect Dis. 2010 Feb;23(1):9-14. doi: 10.1097/QCO.0b013e328334fe84. Review.

PMID:
19996748
11.

Longitudinal evaluation of cardiovascular disease-associated biomarkers in relation to abacavir therapy.

Hammond E, McKinnon E, Mallal S, Nolan D.

AIDS. 2008 Nov 30;22(18):2540-3. doi: 10.1097/QAD.0b013e328319807f. No abstract available.

PMID:
19005279
12.

FDA notifications. Ongoing safety review of abacavir, possible MI risk.

[No authors listed]

AIDS Alert. 2011 May;26(5):58-9. No abstract available.

PMID:
21649950
13.

Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study.

Obel N, Farkas DK, Kronborg G, Larsen CS, Pedersen G, Riis A, Pedersen C, Gerstoft J, Sørensen HT.

HIV Med. 2010 Feb;11(2):130-6. doi: 10.1111/j.1468-1293.2009.00751.x. Epub 2009 Aug 13.

14.

Association between abacavir exposure and increased risk for cardiovascular disease in patients with human immunodeficiency virus.

Schafer JJ, Short WR, Squires KE.

Pharmacotherapy. 2010 Oct;30(10):1072-83. doi: 10.1592/phco.30.10.1072.

PMID:
20874044
15.

FDA notifications. Large study suggests heart attack risk from use of abacavir or didanosine.

[No authors listed]

AIDS Alert. 2008 May;23(5):58-9. No abstract available.

PMID:
18642404
16.

1592 (abacavir): do not rechallenge after hypersensitivity reaction.

James JS.

AIDS Treat News. 1997 Dec 19;(No 285):1, 5.

PMID:
11364916
17.

Labeling changes for abacavir.

[No authors listed]

AIDS Patient Care STDS. 2008 Aug;22(8):683-4. doi: 10.1089/apc.2008.9949. No abstract available.

PMID:
18721055
18.

The abacavir hypersensitivity reaction and interruptions in therapy.

Loeliger AE, Steel H, McGuirk S, Powell WS, Hetherington SV.

AIDS. 2001 Jul 6;15(10):1325-6. No abstract available.

PMID:
11426085
19.

Unusual clinical presentation of hypersensitivity reaction to abacavir.

Aquilina C, Mularczyk M, Lucas F, Viraben R.

AIDS. 2003 Nov 7;17(16):2403-4. No abstract available.

PMID:
14571198
20.

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.

D:A:D Study Group, Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D'Arminio Monforte A, Friis-Møller N, Kirk O, Pradier C, Weller I, Phillips AN, Lundgren JD.

Lancet. 2008 Apr 26;371(9622):1417-26. doi: 10.1016/S0140-6736(08)60423-7. Epub 2008 Apr 2. Erratum in: Lancet. 2008 Jul 26;372(9635):292.

Supplemental Content

Support Center